血清TIMP-1水平对评价非小细胞肺癌化疗疗效的价值  

The value of serum TIMP-1 level for evaluation of the chemotherapeutic efficacy for patients with non-small cell lung carcinoma

作　　者：张兵[1] 郑玉龙[1] 徐跃[1] 周黎阳[1] 刘淑[1] 

机构地区：[1]淮安市第二人民医院呼吸内科,淮安223001

出　　处：《肿瘤》2009年第11期1070-1072,共3页Tumor

摘　　要：目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者化疗前、后血清金属蛋白酶组织抑制剂(tissue inhibitor of metalloproteinase,TIMP)-1的水平及其与化疗疗效的关系。方法:应用ELISA法检测20例健康志愿者及60例晚期NSCLC患者接受吉西他宾+顺铂方案化疗前、后血清TIMP-1水平,并分析其与化疗疗效之间的关系。结果:NSCLC患者化疗前血清TIMP-1水平明显高于健康志愿者(P<0.01);血清TIMP-1水平与肿瘤大小有关(P<0.05),与肿瘤的组织学类型(鳞癌和腺癌)和临床分期(ⅢB和Ⅳ期)无关(P>0.05);NSCLC化疗有效组在化疗结束后7d的血清TIMP-1水平明显低于化疗前(P<0.01);化疗无效组化疗前、后血清TIMP-1水平无明显差异(P>0.05),且化疗前血清TIMP-1水平显著高于化疗有效组和健康志愿者(P<0.01),而后2者的血清TIMP-1水平无明显差异(P>0.05)。结论:NSCLC患者血清TIMP-1水平与化疗疗效有关,高TIMP-1水平提示可能对吉西他滨+顺铂的化疗方案不敏感。Objective：To investigate the change in serum tissue inhibitor of metalloproteinase （TIMP）-I level in patients with non-small cell lung cancer （NSCLC） before and after chemotherapy, and its correlation with efficacy of chemotherapy. Methods：Serum TIMP-1 levels were detected in 20 healthy subjects and 60 patients with advanced NSCLC before and after gemcitabine plus cisplatin chemotherapy by ELISA method. Its correlation with efficacy of chemotherapy was analyzed. Results：Serum TIMP-1 levels in NSCLC group was significantly higher than those in healthy volunteers（ P 〈 0.01 ）. Serum TIMP-1 levels were closely related to tumor size, but not related to the histological classification（ adenocarcinoma and squamous carcinoma）and clinical stage（ 1~ B and 1V ） （P 〉 0.05 ）. Serum TIMP-1 levels in patients who had effective response on day 7 post-chemotherapy were significantly lower than those detected be- fore chemotherapy （P 〈 0.01 ）. There was no significant difference in serum TIMP-1 levels in non-responders before and after chemo- therapy（ P 〉 0.05 ）. The serum TIMP-1 level in non-responders before chemotherapy were significantly higher than those in responders and healthy subjects（P 〈 0.01 ）,while the difference between healthy volunteers and responders was not significant（ P 〉 0.05 ）. Conclusion ： Serum TIMP-1 levels may be closely related to chemotherapy response and high levels of TIMP-1 indicates the NSCLC patients would had no response to gemcitabine and cisplatin （GP） regimen.

关 键 词：癌 非小细胞肺 药物疗法 金属蛋白酶1组织抑制剂 血清学试验 

分 类 号：R734.2[医药卫生—肿瘤]